Assessing the potential success of cystic fibrosis carrier screening: Lessons learned from tay-sachs disease and β-thalassemia

Public Health Genomics

Volumn 13, Issue 5, 2010, Pages 310-319

  Laberge, A M ^a,d   Watts, C ^a,b   Porter, K ^a   Burke, W ^a,c  

^a Institute for Public Health Genetics   (Italy)

^b U S DEPARTMENT OF HEALTH AND HUMAN SERVICES   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF MONTREAL   (Canada)

Author keywords

Beta thalassemia; Carrier screening; Cystic fibrosis; Public health genetics; Tay Sachs disease

Indexed keywords

ARTICLE; BETA THALASSEMIA; COMMUNITY ASSESSMENT; COMPARATIVE STUDY; CONSUMER ADVOCACY; CYPRUS; CYSTIC FIBROSIS; DIAGNOSTIC TEST; DISEASE CARRIER; DISEASE COURSE; DISEASE SEVERITY; GENETIC SCREENING; HIGH RISK POPULATION; HUMAN; INTERVIEW; JEW; OUTCOME ASSESSMENT; PATIENT DECISION MAKING; PATIENT PARTICIPATION; PRIORITY JOURNAL; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SUPPORT GROUP; TAY SACHS DISEASE; UNITED STATES; GENETICS; HETEROZYGOTE DETECTION;

BETA-THALASSEMIA; CYSTIC FIBROSIS; GENETIC TESTING; HETEROZYGOTE DETECTION; HUMANS; TAY-SACHS DISEASE; GENETIC CARRIER SCREENING;

EID: 77954244632     PISSN: 16624246     EISSN: None     Source Type: Journal    
DOI: 10.1159/000253122     Document Type: Article

References (77)

1. Kaback MM, Nathan TJ, Greenwald S: Tay- Sachs disease: heterozygote screening and prenatal diagnosis - U.S. experience and world perspective. Prog Clin Biol Res 1977; 18: 13-36.
2. Cao A, Rosatelli MC, Monni G, Galanello R: Screening for thalassemia: a model of success. Obstet Gynecol Clin North Am 2002; 29: 305-328.
3. Kaback MM: Population-based genetic screening for reproductive counseling: the Tay-Sachs disease model. Eur J Pediatr 2000;159(suppl 3):S192-S195.
4. Marx JL: The cystic fibrosis gene is found. Science 1989; 245: 923-925.
5. Genetic testing for cystic fibrosis. NIH Consens Statement 1997; 15: 1-37.
6. Richards CS, Bradley LA, Amos J, Allitto B, Grody WW, Maddalena A, McGinnis MJ, Prior TW, Popovich BW, Watson MS, Palomaki GE: Standards and guidelines for CFTR mutation testing. Genet Med 2002; 4: 379-391.
7. Chodirker BN, Cadrin C, Davies GAL, Summers AM, Wilson RD, Winsor EJT, Young D: Canadian guidelines for prenatal diagnosis - genetic indications for prenatal diagnosis. J Soc Obstet Gynaecol Can 2001; 23: 525-531.
8. Comité Consultatif National d'Ethique pour les sciences de la vie et de la santé. Le dépistage prénatal géné ralisé de la mucoviscidose. 2004. Report No. 83. Available at http:// www.ccne-ethique.fr/docs/fr/avis083.pdf, accessed 08/28/09.
9. Department of Health, National Screening Committee, UK: U.K. National Screening Committee - cystic fibrosis screening (in pregnancy). 2006. Available at http://www. screening.nhs.uk/cysticfibrosis-pregnancy, accessed 08/28/09.
10. Murray J, Cuckle H, Taylor G, Littlewood J, Hewison J: Screening for cystic fibrosis. Health Technol Assess 1999; 3: 1-104.
11. Morgan MA, Driscoll DA, Mennuti MT, Schulkin J: Practice patterns of obstetriciangynecologists regarding preconception and prenatal screening for cystic fibrosis. Genet Med 2004; 6: 450-455.
12. Morgan MA, Driscoll DA, Zinberg S, Schulkin J, Mennuti MT: Impact of self-reported familiarity with guidelines for cystic fibrosis carrier screening. Obstet Gynecol 2005; 105: 1355-1361.
13. Zinberg RE, Kornreich R, Edelmann L, Desnick RJ: Prenatal genetic screening in the Ashkenazi Jewish population. Clin Perinatol 2001; 28: 367-382.
14. Kaback MM, Desnick RJ: Tay-Sachs disease: from clinical description to molecular defect. Adv Genet 2001; 44: 1-9.
15. Modell B, Khan M, Darlison M: Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet 2000; 355: 2051-2052.
16. Olivieri NF: The beta-thalassemias. N Engl J Med 1999; 341: 99-109.
17. Cao A: Results of programmes for antenatal detection of thalassemia in reducing the incidence of the disorder. Blood Rev 1987; 1: 169-176.
18. Angastiniotis MA, Hadjiminas MG: Prevention of thalassaemia in Cyprus. Lancet 1981; 1: 369-371.
19. O'Brien JS, Okada S, Chen A, Fillerup DL: Tay-Sachs disease. Detection of heterozygotes and homozygotes by serum hexosaminidase assay. N Engl J Med 1970; 283: 15-20.
20. Triggs-Raine BL, Feigenbaum AS, Natowicz M, Skomorowski MA, Schuster SM, Clarke JT, Mahuran DJ, Kolodny EH, Gravel RA: Screening for carriers of Tay-Sachs disease among Ashkenazi Jews. A comparison of DNA-based and enzyme-based tests. N Engl J Med 1990; 323: 6-12.
21. Fernandes MJ, Kaplan F, Clow CL, Hechtman P, Scriver CR: Specificity and sensitivity of hexosaminidase assays and DNA analysis for the detection of Tay-Sachs disease gene carriers among Ashkenazic Jews. Genet Epidemiol 1992; 9: 169-175.
22. Cao A: Carrier screening and genetic counselling in beta-thalassemia. Int J Hematol 2002; 76(suppl 2):105-113.
23. Guterman L: Choosing eugenics: how far will nations go to eliminate a genetic disease? Chron High Educ 2003; 49:A22-A24, A26.
24. Cao A, Furbetta M, Galanello R, Melis MA, Angius A, Ximenes A, Rosatelli C, Ruggeri R, Addis M, Tuveri T, Falchi AM, Paglietti E, Scalas MT: Prevention of homozygous betathalassemia by carrier screening and prenatal diagnosis in Sardinia. Am J Hum Genet 1981; 33: 592-605.
25. Cao A, Rosatelli C, Galanello R, Monni G, Olla G, Cossu P, Ristaldi MS: The prevention of thalassemia in Sardinia. Clin Genet 1989; 36: 277-285.
26. Mitchell JJ, Capua A, Clow C, Scriver CR: Twenty-year outcome analysis of genetic screening programs for Tay-Sachs and betathalassemia disease carriers in high schools. Am J Hum Genet 1996; 59: 793-798.
27. Kaback MM: Screening and prevention in Tay-Sachs disease: origins, update, and impact. Adv Genet 2001; 44: 253-265.
28. Cao A, Saba L, Galanello R, Rosatelli MC: Molecular diagnosis and carrier screening for beta thalassemia. JAMA 1997; 278: 1273-1277.
29. Cowan RS: Heredity and Hope: The Case for Genetic Screening. Cambridge, Harvard University Press, 2008, p 292.
30. Ekstein J, Katzenstein H: The Dor Yeshorim story: community-based carrier screening for Tay-Sachs disease. Adv Genet 2001; 44: 297-310.
31. Kornreich R, Ekstein J, Edelmann L, Desnick RJ: Premarital and prenatal screening for cystic fibrosis: experience in the Ashkenazi Jewish population. Genet Med 2004; 6: 415-420.
32. Modell B, Khan M, Darlison M, King A, Layton M, Old J, Petrou M, Varnavides L: A national register for surveillance of inherited disorders: beta thalassaemia in the United Kingdom. Bull World Health Organ 2001; 79: 1006-1013.
33. Statement of the American Society of Human Genetics on cystic fibrosis carrier screening. Am J Hum Genet 1992; 51: 1443-1444.
34. Mennuti MT: Lights! Camera! Action! Obstet Gynecol 2001; 98: 539-541.
35. Cystic Fibrosis Foundation: Patient Registry Annual Data Report 2007. Available at http:// www.cff.org/UploadedFiles/research/ClinicalResearch/ 2007-Patient-Registry-Report. pdf, accessed 08/28/09.
36. Lai HJ, Cheng Y, Farrell PM: The survival advantage of patients with cystic fibrosis diagnosed through neonatal screening: evidence from the United States Cystic Fibrosis Foundation registry data. J Pediatr 2005; 147(suppl 3):S57-S63.
37. Ratjen F, Doring G: Cystic fibrosis. Lancet 2003; 361: 681-689.
38. FitzSimmons SC: The changing epidemiology of cystic fibrosis. J Pediatr 1993; 122: 1-9.
39. Rigoli L, Meo A, Miceli MR, Alessio K, Caruso RA, La Rosa MA, Salpietro DC, Ricca M, Barberi I: Molecular analysis of betathalassaemia patients in a high incidence area of southern Italy. Clin Lab Haematol 2001; 23: 373-378.
40. Salvatore F, Scudiero O, Castaldo G: Genotype- phenotype correlation in cystic fibrosis: the role of modifier genes. Am J Med Genet 2002; 111: 88-95.
41. Davis PB: Cystic fibrosis since 1938. Am J Respir Crit Care Med 2006; 173: 475-482.
42. Super M, Abbott J: Genetic advances in cystic fibrosis: to screen, to treat or both? Disabil Rehabil 1998; 20: 202-208.
43. Grosse SD, Boyle CA, Botkin JR, Comeau AM, Kharrazi M, Rosenfeld M, Wilfond BS; CDC: Newborn screening for cystic fibrosis: evaluation of benefits and risks and recommendations for state newborn screening programs. MMWR Recomm Rep 2004; 53: 1-36.
44. Rosenfeld M: Overview of published evidence on outcomes with early diagnosis from large US observational studies. J Pediatr 2005; 147(suppl 3):S11-S14.
45. Monaghan KG, Highsmith WE, Amos J, Pratt VM, Roa B, Friez M, Pike-Buchanan LL, Buyse IM, Redman JB, Strom CM, Young AL, Sun W: Genotype-phenotype correlation and frequency of the 3199del6 cystic fibrosis mutation among I148T carriers: results from a collaborative study. Genet Med 2004; 6: 421-425.
46. Watson MS, Cutting GR, Desnick RJ, Driscoll DA, Klinger K, Mennuti M, Palomaki GE, Popovich BW, Pratt VM, Rohlfs EM, Strom CM, Richards CS, Witt DR, Grody WW: Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel. Genet Med 2004; 6: 387-391.
47. Palomaki GE, FitzSimmons SC, Haddow JE: Clinical sensitivity of prenatal screening for cystic fibrosis via CFTR carrier testing in a United States panethnic population. Genet Med 2004; 6: 405-414.
48. ACOG committee opinion. Number 298, August 2004. Prenatal and preconceptional carrier screening for genetic diseases in individuals of Eastern European Jewish descent. Obstet Gynecol 2004; 104: 425-428.
49. Cystic Fibrosis Foundation: Testing for cystic fibrosis - genetic carrier testing. Available at http://www.cff.org/AboutCF/Testing/GeneticCarrierTest/, accessed 08/28/09.
50. Doherty RA, Palomaki GE, Kloza EM, Erickson JL, Haddow JE: Couple-based prenatal screening for cystic fibrosis in primary care settings. Prenat Diagn 1996; 16: 397-404.
51. Witt DR, Schaefer C, Hallam P, Wi S, Blumberg B, Fishbach A, Holtzman J, Kornfeld S, Lee R, Nemzer L, Palmer R: Cystic fibrosis heterozygote screening in 5,161 pregnant women. Am J Hum Genet 1996; 58: 823-835.
52. Grody WW, Dunkel-Schetter C, Tatsugawa ZH, Fox MA, Fang CY, Cantor RM, Novak JM, Bass HN, Crandall BF: PCR-based screening for cystic fibrosis carrier mutations in an ethnically diverse pregnant population. Am J Hum Genet 1997; 60: 935-947.
53. Mischler EH, Wilfond BS, Fost N, Laxova A, Reiser C, Sauer CM, Makholm LM, Shen G, Feenan L, McCarthy C, Farrell PM: Cystic fibrosis newborn screening: impact on reproductive behavior and implications for genetic counseling. Pediatrics 1998; 102: 44-52.
54. Wei S, Quigg MH, Monaghan KG: Is cystic fibrosis carrier screening cost effective? Community Genet 2007; 10: 103-109.
55. Hale JE, Parad RB, Comeau AM: Newborn screening showing decreasing incidence of cystic fibrosis. N Engl J Med 2008; 358: 973-974.
56. Mennie ME, Gilfillan A, Compton M, Curtis L, Liston WA, Pullen I, Whyte DA, Brock DJ: Prenatal screening for cystic fibrosis. Lancet 1992; 340: 214-216.
57. Brock DJ: Prenatal screening for cystic fibrosis: 5 years experience reviewed. Lancet 1996; 347: 148-150.
58. Nielsen R, Gyrd-Hansen D: Prenatal screening for cystic fibrosis: an economic analysis. Health Econ 2002; 11: 285-299.
59. Brambati B, Tului L, Fattore S: First-trimester fetal screening of cystic fibrosis in lowrisk population. Lancet 1993; 342: 624.
60. Livingstone J, Axton RA, Gilfillan A, Mennie M, Compton M, Liston WA, Calder AA, Gordon AJ, Brock DJ: Antenatal screening for cystic fibrosis: a trial of the couple model. BMJ 1994; 308: 1459-1462.
61. Miedzybrodzka ZH, Hall MH, Mollison J, Templeton A, Russell IT, Dean JC, Kelly KF, Marteau TM, Haites NE: Antenatal screening for carriers of cystic fibrosis: randomised trial of stepwise v couple screening. BMJ 1995; 310: 353-357.
62. Clausen H, Brandt NJ, Schwartz M, Skovby F: Psychological and social impact of carrier screening for cystic fibrosis among pregnant women - a pilot study. Clin Genet 1996; 49: 200-205. (Pubitemid 26237104)
63. Scotet V, Audrezet MP, Roussey M, Rault G, Blayau M, De Braekeleer M, Ferec C: Impact of public health strategies on the birth prevalence of cystic fibrosis in Brittany, France. Hum Genet 2003; 113: 280-285.
64. Lane B, Williamson P, Dodge JA, Harris H, Super M, Harris R: Confidential inquiry into families with two siblings with cystic fibrosis. Arch Dis Child 1997; 77: 501-503.
65. Borgo G, Fabiano T, Perobelli S, Mastella G: Effect of introducing prenatal diagnosis on the reproductive behaviour of families at risk for cystic fibrosis. A cohort study. Prenat Diagn 1992; 12: 821-830.
66. Boue J, Muller F, Simon-Bouy B, Faure C, Boue A: Consequences of prenatal diagnosis of cystic fibrosis on the reproductive attitudes of parents of affected children. Prenat Diagn 1991; 11: 209-214.
67. Baranov VS, Gorbunova VN, Ivaschenko TE, Shwed N, Osinovskaya NS, Kascheeva TK, Lebedev VM, Mikhailov AV, Vakharlovsky VG, Kuznetzova TV: Five years experience of prenatal diagnosis of cystic fibrosis in the former U.S.S.R. Prenat Diagn 1992; 12: 575-586.
68. Super M, Schwarz MJ: Mutations of the cystic fibrosis gene locus within the population of the Northwest of England. Eur J Pediatr 1992; 151: 108-111.
69. Super M, Schwarz MJ, Malone G, Roberts T, Haworth A, Dermody G: Active cascade testing for carriers of cystic fibrosis gene. BMJ 1994; 308: 1462-1467. (Pubitemid 24170165)
70. Casals T, Gimenez J, Ramos MD, Nunes V, Estivill X: Prenatal diagnosis of cystic fibrosis in a highly heterogeneous population. Prenat Diagn 1996; 16: 215-222.
71. Dudding T, Wilcken B, Burgess B, Hambly J, Turner G: Reproductive decisions after neonatal screening identifies cystic fibrosis. Arch Dis Child Fetal Neonatal Ed 2000; 82: F124-F127.
72. Henneman L, Bramsen I, Van Os TA, Reuling IE, Heyerman HG, van der Laag J, van der Ploeg HM, ten Kate LP: Attitudes towards reproductive issues and carrier testing among adult patients and parents of children with cystic fibrosis (CF). Prenat Diagn 2001; 21: 1-9.
73. Henneman L, Kooij L, Bouman K, ten Kate LP: Personal experiences of cystic fibrosis (CF) carrier couples prospectively identified in CF families. Am J Med Genet 2002; 110: 324-331.
74. Wilfond BS, Parad RB, Fost N: Balancing benefits and risks for cystic fibrosis newborn screening: implications for policy decisions. J Pediatr 2005;147(suppl 3):S109-S113.
75. Farrell PM, Lai HJ, Li Z, Kosorok MR, Laxova A, Green CG, Collins J, Hoffman G, Laessig R, Rock MJ, Splaingard ML: Evidence on improved outcomes with early diagnosis of cystic fibrosis through neonatal screening: enough is enough! J Pediatr 2005;147(suppl 3):S30-S36. (Pubitemid 41400256)
76. Cystic Fibrosis Foundation: Testing for cystic fibrosis - Newborn Screening. Available at http://www.cff.org/AboutCF/Testing/NewbornScreening/, accessed 08/28/09.
77. Pletcher BA, Gross SJ, Monaghan KG, Driscoll DA, Watson MS: The future is now: carrier screening for all populations. Genet Med 2008; 10: 33-36.